United States v. Azubueze Ikejiani

630 F. App'x 933
CourtCourt of Appeals for the Eleventh Circuit
DecidedOctober 30, 2015
Docket15-10486
StatusUnpublished
Cited by1 cases

This text of 630 F. App'x 933 (United States v. Azubueze Ikejiani) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Azubueze Ikejiani, 630 F. App'x 933 (11th Cir. 2015).

Opinion

PER CURIAM:

In this direct appeal, Azubueze Ikejiani - appeals his conviction and 11-month sentence imposed after pleading guilty to one count of holding misbranded prescription drugs for sale in interstate commerce, in violation of 21 U.S.C. § 331(k). Following a careful review of the record and briefs, we affirm.

I. BACKGROUND

A. Offense Conduct

We recount the facts from Ikejiani’s factual proffer, his guilty plea colloquy, his sentencing hearing, and the presentence investigation report (“PSI”). Ikejiani is a licensed pharmacist. In 2006, Ikejiani, through his company Kanec (USA), Inc., manufactured and distributed approximately 240,000 capsules of a product called “XOX For Men” (“XOX”) without a prescription. In March 2007, Canadian health authorities issued a warning and recall of XOX because it contained tadalafil, the active ingredient in the prescription erectile dysfunction drug Cialis. Ikejiani admitted to Food and Drug Administration (“FDA”) investigators that he had manufactured and distributed XOX, as well as another product called “Stud Capsule for Men” (“Stud”), but claimed that he had discontinued manufacturing these items by April 2007.

In January 2010, an individual purchased some Stud capsules manufactured and distributed by Ikejiani, ingested one, and suffered an adverse reaction. On February 5, 2010, that individual reported the adverse reaction to FDA agents and provided them with his remaining Stud capsules. Testing revealed that the Stud capsules contained twice the maximum prescription dosage of sildenafil citrate, the active ingredient in the prescription erectile dysfunction drug Viagra.

In March 2010, the FDA conducted another investigation of Ikejiani. Ikejiani admitted that he manufactured and distributed Stud using raw materials imported from India. While Ikejiani claimed that he did not know that Stud contained active pharmaceutical ingredients, emails recovered pursuant to a search warrant revealed that Ikejiani specifically ordered sil-denafil citrate by name in large quantities for various shipments. FDA investigators advised Ikejiani to stop selling products that contained sildenafil citrate and tada-lafil, and' Ikejiani assured them that he would no longer sell or distribute such products.

Nevertheless, in December 2010, the FDA discovered that Ikejiani continued to manufacture and distribute a product called “Nite Rider,” which contained silde- *935 nafil citrate. On January 7, 2011, FDA investigators interviewed Ikejiani again. Ikejiani admitted to the continuing manufacture and sale of Nite Rider, but denied putting any active pharmaceutical ingredients in his products. Ultimately, investigators recovered invoices proving that, between 2007 and 2010, Ikejiani sold $413,428 worth of products containing sil-denafil citrate and tadalafil to wholesale customers without a prescription.

B. Criminal Information and Guilty Plea

On September 19, 2014, the government charged Ikejiani by criminal information with one count of holding misbranded drugs for sale in interstate commerce with intent to defraud, in violation of 21 U.S.C. § 331(k). Ikejiani initially pleaded not guilty, but later pleaded guilty without the benefit of a plea agreement.

At a November 7, 2014 change of plea hearing, the district court placed Ikejiani under oath and informed him that he could be prosecuted for perjury if he made any false statements. Ikejiani testified that he understood the purpose of the hearing, read the criminal information in'its entirety, understood the charges against him him, discussed the evidence with his attorney, and understood everything his attorney had told him about the case. The court then read the criminal information aloud, and Ikejiani confirmed that he understood the charge against him.

Ikejiani also confirmed that he read the written factual proffer in its entirety and signed it. Moreover, the factual proffer was explained by Ikejiani’s attorney, Ike-jiani understood everything in it, and Ike-jiani confirmed that all of the facts set forth therein were true and accurate. The district court then informed Ikejiani of the consequences of pleading guilty, including the forfeiture of several rights. The district court ultimately accepted Ikejiani’s guilty plea and adjudicated him guilty of the charged offense.

C. Sentencing

The PSI recommended a base offense level of six, pursuant to U.S.S.G. § 2N2.1(c)(l). The PSI added to that base offense level: (1) a 14-level increase because the loss value was more than $400,000 but less than $1,000,000, § 2Bl.l(b)(l)(H); (2) a two-level increase because the offense involved ten or more victims, § 2Bl.l(b)(2)(A); (3) a two-level increase because the offense involved the conscious risk of death or serious bodily injury, § 2Bl.l(b)(15)(A); (4) a two-level increase because Ikejiani abused a position of trust or used a special skill in the commission or concealment of the offense, § 3B1.3; and (5) a three-level reduction for acceptance of responsibility and cooperation with authorities, § 3El.l(a) and (b).

Ikejiani’s total adjusted offense level was 23. Based on this total offense level and a criminal history category of I, Ike-jiani’s advisory guidelines range was 46 to 57 months’ imprisonment. However, because the statutory maximum term of imprisonment was 1 year, the advisory guidelines range became 12 months, pursuant to U.S.S.G. § 5Gl.l(a).

At sentencing, Ikejiani’s counsel requested a sentence that did not include a term of confinement. In support of his request, Ikejiani’s counsel noted that he accepted full responsibility for his crime and was fully cooperative with the government. Ikejiani’s counsel further noted that nobody suffered great bodily harm from consuming Ikejiani’s products, but did not explicitly object to the enhancements in the PSI.

*936 Ikejiani’s counsel also argued that Ike-jiani’s personal history and background weighed in favor of non-confinement. Specifically, Ikejiani was forced into military service as a teenager during a Nigerian civil war, had been law abiding for the four or five years after the offense conduct, did not pose a risk of harm to the public, was not a violent individual, and was the sole provider for his large family.

Ikejiani personally addressed the court and apologized for his actions. The district court asked questions regarding the health risk that Ikejiani’s misbranded products posed, and Ikejiani acknowledged the risk and apologized. Ikejiani then informed the court that he suffered from benign prostate hyperplasia, supported his children in college, and volunteered for disaster relief efforts.

The government requested the maximum 12-months’ imprisonment sentence, emphasizing the seriousness of Ikejiani’s offense, his specialized knowledge, and his repeated fraudulent behavior.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Svirskiy
989 F.3d 88 (First Circuit, 2021)

Cite This Page — Counsel Stack

Bluebook (online)
630 F. App'x 933, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-azubueze-ikejiani-ca11-2015.